Several evidences support the hypothesis that glutamatergic dysfunction may be implicated in the pathogenesis of schizophrenia and in the last few years great interest has been focused on the role of the N-methyl-D-aspartate receptor (NMDAR). Glutamate is the main excitatory neurotransmitter in human CNS and it plays a prominent role in synaptic plasticity, learning, and memory and other cognitive functions. Increasing interest in memantine add-on therapy in schizophrenic patients with negative and cognitive symptoms may suggest that memantine could be a new promising treatment in schizophrenia. The aim of this update was to evaluate clinical data about the memantine effectiveness in schizophrenic patients. Our systematic review of the literature highlights that memantine therapy in schizophrenic patients seems to improve mainly negative symptoms while positive symptoms and cognitive symptoms did not improve significantly.
A study aimed at contributing to the elucidation of the decrease in serum rifampicin concentrations observed during repeated administration of the antibiotic was carried out in a group of 18 healthy subjects. Three dose levels were investigated: 900 mg once daily, 600 mg once daily and 300 mg 12-hourly, and the behaviour over a period of 14 days of the peak and 12-hour serum concentrations and of the biological half-life was evaluated. The study demonstrates that during treatment with repeated doses of rifampicin the kinetics of the antibiotic undergo definite changes. While the peak serum concentrations do not appear to be affected in a consistent way by the duration of treatment, the 12-hour serum concentrations show a definite decrease, which takes place mainly during the first 6 days of treatment; a further decrease between 6 and 14 days was seen but was found not to be significant. A definite decrease in biological half-life is also observed during the first 6 days of treatment; such a decrease is directly correlated with the dose given on each administration. As a consequence, the half-life values, which are correlated with the doses on the first day of treatment, are no longer different for the different doses on the sixth day. The hypothesis that the increase in rate of disappearance of rifampicin from blood, which takes place mainly during the first 6 days of treatment, is due to an increased rate of biliary excretion is discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.